gv
-
Allara Snags $10M to Scale Its Platform for Women’s Chronic Hormonal Conditions
Allara raised $10 million in a Series A funding round led by GV. The startup offers membership-based virtual services to treat women’s chronic hormonal conditions, such as PCOS and endometriosis. CEO Rachel Blank — former executive at Ro and investor at General Catalyst — founded the company partly due to the difficulty she experienced arriving at her own PCOS diagnosis.
-
Investors funnel $40M into high-tech benefits brokerage
Armed with fresh capital, Nava Benefits hopes to take advantage of what it believes will be a disruption in the way smaller businesses approach health and wellness benefits, including the many digital tools now on the market.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Corporate venture capital-backed funding for digital health startups increased sharply in 2021
According to a CB Insight’s report, GV (formerly Google Ventures) funded the most digital health companies with 22 investments, making it most active investor in that sector for four years in a row.
-
Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically “undruggable” targets using a process known as protein degradation.
-
Startups, Artificial Intelligence
Decentralized research platform Owkin raises another $18M for series A
Owkin, a startup building a decentralized health research platform, rounded out its series A round with another $18 million in funding. It uses federated learning to allow researchers to collaborate on AI models while keeping data onsite.
-
Sana Biotechnology raises more than $700M for cell, gene therapy efforts
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics – one of the earliest commercial developers of CAR-T cell therapy technology – in 2013.
-
Health IT, Startups, BioPharma
RDMD raises $14M for rare disease real-world evidence generation
The San Francisco-based startup is one of several that have been raising money over the past couple of weeks in areas like neurology, oncology and women’s health.
-
Health IT, Artificial Intelligence, Health Tech
How Verana went from a pivot to a $100M funding round
After Miki Kapoor joined Verana Health in 2018, the company shifted from a tele-ophthalmology startup to a data analytics company. Since then, Verana has raised $100 million in funding led by GV and made its first major acquisition.
-
Alphabet’s GV leads $100M investment in Verana Health
GV, formerly known as Google Ventures, led a $100 million funding round in Verana Health. The San Francisco-based company aggregates clinical data for medical research and analytics.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
With $200M Series A, EQRx aims to tackle high drug prices
The startup, founded by a prominent health policy expert and a biotech industry executive, aims to bring down the cost of drugs by re-engineering and making less costly the process by which they are discovered and brought to patients.
-
Kronos Bio bags $105M in Series A round for platform technology
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after “undruggable” targets.
-
Verve Therapeutics aims to tackle heart disease through gene editing
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
-
Arrakis spices up development efforts with $75M Series B round for RNA-targeting drugs
The company has raised more than $100 million since 2017 and plans to use the current funding to build a pipeline of RNA-targeting small molecules.
-
Single-letter gene editing startup Beam Therapeutics raises $135M Series B round
The company is developing means using CRISPR/Cas9 to edit genomes at the single-letter level, as opposed to the DNA- and RNA-cutting method usually employed.
-
Maze Therapeutics launches with nearly $200M to explore genetic modifiers’ role in disease
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.